Biosimilars in the EU – Information guide for healthcare professionals – now available in 23 languages

English

(PDF/1.85 MB)

Bulgarian

(PDF/1.82 MB)
Croatian

(PDF/1.81 MB)
Czech

(PDF/1.86 MB)
Danish

(PDF/1.84 MB)
Dutch

(PDF/1.83 MB)
Estonian

(PDF/656.54 KB)
Finnish

(PDF/1.79 MB)
French

(PDF/1.86 MB)
German

(PDF/1.9 MB)
Greek

(PDF/1.84 MB)
Hungarian

(PDF/1.86 MB)
Italian

(PDF/1.85 MB)
Latvian

(PDF/1.8 MB)
Lithuanian

(PDF/1.81 MB)
Maltese

(PDF/710.75 KB)
Polish

(PDF/1.87 MB)
Portuguese

(PDF/1.85 MB)
Romanian

(PDF/1.86 MB)
Slovak

(PDF/1.86 MB)
Slovenian

(PDF/1.86 MB)
Spanish

(PDF/1.84 MB)
Swedish

(PDF/1.84 MB)

EMA Information Session on Biosimilars for Patients and… 5 March 2015
Industry Welcomes the 3rd European Commission Workshop on… 5 May 2017 The European pharmaceutical industry welcomes the 3rd workshop on access…
European Commission Question & Answer Document for… 25 October 2016 Today, the European Commission published a Q&A for patients on…
IMS – The Impact of Biosimilar Competition (2015) 1 November 2015 This document sets out to describe the effects on price,…